Category: drug design

Prostate cancer paper retracted after investigation can’t review original image

1.coverAn article about how a COX-2 inhibitor (celecoxib) inhibits growth of prostate cancer in rats is being retracted after the authors were unable to provide an investigation committee at New York University with the backup they were asking for.

When the paper was published in 2003, first author Bhagavathi Narayanan worked at the Institute for Cancer Prevention in New York (also known as the American Health Foundation). But when the institute went broke the next year — thanks partly to lavish salaries and offices, as the New York Post reported —  the authors claim they could no longer obtain back up for an image in the paper, once it was questioned years later by NYU, where Narayanan is now based.

Here’s the retraction note, published in Clinical Cancer Research:

Continue reading Prostate cancer paper retracted after investigation can’t review original image

New developments cause authors to pull paper on drugs’ environmental impact

integrated envThe authors of an article about the effects of pharmaceutical drugs on the environment have retracted it before publishing the final version due to new developments in the field, which would have required a major revision.

The authors pulled the paper from Integrated Environmental Assessment and Management before it went through the final publication process – such as copyediting and proofreading – after they learned about new findings related to assessing to the risks of human exposures to pharmaceuticals in the environment.

We’d try to figure out which portions of the paper might need updating, but publisher Wiley recently pulled the original article and abstract, against the journal editor’s wishes.

Here’s the retraction note: Continue reading New developments cause authors to pull paper on drugs’ environmental impact

Oh no he didn’t! Misattributed Aristotle work leads to correction in highly cited cancer paper

jcoJohn Shannon may be a mere undergrad at Hillsdale College in Michigan, but he knows enough about history to be surprised that Aristotle had written an entire book about economics that Shannon had never heard of.

That curiosity led to the discovery that a highly cited paper about pricing in cancer drugs was missing a reference to a rather relevant source about a treatise by the Greek philosopher, prompting the Journal of Clinical Oncology to correct the paper. But to Shannon, a missing reference is not the only problem with the paper.

As he notes in an essay in Public Discourse, Shannon’s interest was piqued when he noticed this passage in a 2013 paper in the Journal of Clinical Oncology on the fair price — “just price,” or Justum Pretium — of cancer drugs: Continue reading Oh no he didn’t! Misattributed Aristotle work leads to correction in highly cited cancer paper

“The peer review process was compromised”: Inflammation drug paper pulled

12

A paper that screened for antibodies that target TNFα, a major source of inflammation, has been retraction after an investigation revealed the peer-review process may have been compromised.

We’ve seen the peer review process “compromised” in a handful of ways — from a mathematician who oversaw the process on several of his own papers, to some 250 papers subject to outright fake peer review. The note for this paper, published in Amino Acids, doesn’t go into details, so we can only wonder what happened in this particular case.

Here’s the note for “Structure‑based development and optimization of therapy antibody drugs against TNFα:”

Continue reading “The peer review process was compromised”: Inflammation drug paper pulled

Plagiarized figure hurts arthritis paper

Screen Shot 2015-12-03 at 10.49.37 AM

A paper on a way to inhibit arthritis has been retracted following an investigation confirming that it plagiarizes a figure from another paper on the same topic.

The paper, “Blockade of 11β-hydroxysteroid dehydrogenase type 1 enzyme inhibits experimental collagenase-induced osteoarthritis,” was published in Molecular Medicine Reports. A figure claims to show cartilage treated with a specific inhibitor:

Screen Shot 2015-12-03 at 12.06.56 PM

The retraction note tells us that the authors reproduced the figure from another paper in Inflammation — which describes a different inhibitor:

Continue reading Plagiarized figure hurts arthritis paper

A bacterium may be anti-fungal, but it’s not anti-retraction

6

The authors of a paper on an anti-fungal bacterium couldn’t ward off a very common problem: plagiarism. The people credited on the paper, published in Applied Microbiology and Biotechnology, apparently weren’t the original authors, according to the retraction note.

We’re not sure who the original authors are. The retraction note doesn’t elaborate much:

Continue reading A bacterium may be anti-fungal, but it’s not anti-retraction

When a paper is retracted, so is its previous correction–sometimes

1-s2.0-S0968089612X0018X-cov150hSometimes, the path to correcting the scientific record takes a few turns. In the case of a paper about a new cancer compound, authorship issues led to a correction and, ultimately, a retraction — along with a double-back to retract the earlier correction.

We reported on the first part of the story back in January: A 2011 paper that described a novel compound that could work as a drug for the side effects of chemotherapy was corrected in 2012 to add additional authors. But once the authors realized their supposedly novel compound had actually been synthesized by another author, they decided to retract the paper from Bioorganic and Medicinal Chemistry earlier this year, concluding “these facts made the paper inappropriate and unfaithful.”

Apparently, around the same time, the authors decided to retract the earlier correction, as well:

Continue reading When a paper is retracted, so is its previous correction–sometimes

Intellectual property issues sink cancer paper in JACS

176 spine minimum. full size. Editor: Lingling JEM: Leslie RTP: Michael ReidThe authors of a paper on a mechanism for potential cancer therapies are retracting it after realizing they published some proprietary findings “without permission and agreement from St. Jude Children’s Research Hospital.”

According to the retraction note in Journal of the American Chemical Society, the authors included an X-ray crystal structure and data that were gathered at St. Jude’s and considered the hospital’s intellectual property. On the paper, the last author, Zhengding Su, listed an affiliation at St. Jude and Hubei University of Technology in China, along with Amersino Biodevelop Inc., based in Waterloo, Canada.

Here’s the note for “Efficient Reactivation of p53 in Cancer Cells by a Dual MdmX/Mdm2 Inhibitor:”  Continue reading Intellectual property issues sink cancer paper in JACS

Cholesterol paper duplicated; “The authors believed that they had taken the necessary steps to withdraw.”

Biological Reviews

A review journal is pulling a 2013 article about advances in researchers’ understanding of cholesterol after seeing the same article in another journal.

Although the retracted paper appeared first — online in Biological Reviews in February, 2013 — the journal decided to retract it after learning the authors had initially submitted it elsewhere. The first submission was eventually published (with the exception of one author) in 2014 in Frontiers in Bioscience. 

The authors say they “believed that they had taken the necessary steps to withdraw their paper from Frontiers in Bioscience before they submitted to Biological Reviews in June 2012.” Here’s more from the retraction notice:

Continue reading Cholesterol paper duplicated; “The authors believed that they had taken the necessary steps to withdraw.”

“Falsified” data shelve two more drug studies from discredited U Colorado student

The authors of a pair of papers in Molecular Pharmaceutics are retracting them following an investigation at the University of Colorado Denver, which found a graduate student had faked data.

Rajendra Kadam was a prominent member of the Research lab of Uday B. Kompella, until the investigation revealed earlier this year that he had “falsified” data from a liquid chromatography-mass spectroscopy (LC-MS) machine for years.

So far, we’ve found four retractions (including the latest two) and one expression of concern for Kadam. There may be more on the way: Continue reading “Falsified” data shelve two more drug studies from discredited U Colorado student